Recent news on Trelstar

Paladin Reports 2007 First Quarter Financial Results & Increases ...  -  May 10, 2007
CCNMatthews (press release),This increase was primarily attributed to increased promotion activities relating to Paladin's launch of Pennsaid ® , Metadol ® , Trelstar and PravASA ®

Paladin Reports Record 2006 Fourth Quarter and Year End Results  -  Feb 15, 2007
PharmaLive.com (press release),Revenues from the Company's key promoted brands including: Twinject®, Oxytrol®, Estring®, Plan B®, Trelstar®, and Pennsaid® increased by 58% in the fourth

Paladin Reports Record 2006 Fourth Quarter and Year End Results  -  Feb 15, 2007
Genetic Engineering News (press release),Revenues from the Company's key promoted brands including: Twinject(R), Oxytrol(R), Estring(R), Plan B(R), Trelstar(R), and Pennsaid(R) increased by 58% in

Paladin Reports Record 2006 Fourth Quarter and Year End Results  -  Feb 15, 2007
CCNMatthews (press release),Revenues from the Company's key promoted brands including: Twinject ® , Oxytrol ® , Estring ® , Plan B ® , Trelstar ® , and Pennsaid ® increased by 58% in

McGuinty Government Improves Access To Drugs  -  Dec 20, 2006
CNW Telbec (Communiqués de presse),Aranesp (Cancer chemotherapy-related anemia) - Eprex (Cancer chemotherapy-related anemia) - Trelstar (Prostate Cancer) - Gleevec (Cancer-treatment of

McGuinty Government Improves Access To Drugs  -  Dec 20, 2006
Canada NewsWire (press release),Cardiovascular drug) - Viread (HIV/AIDS) - Aranesp (Cancer chemotherapy-related anemia) - Eprex (Cancer chemotherapy-related anemia) - Trelstar (Prostate Cancer ...

Paladin and Auxilium Sign Exclusive Distribution Agreement for ...  -  Dec 12, 2006
Market Wire (press release)...of the testosterone replacement market and will further strengthen our growing urology franchise which includes Oxytrol® and Trelstar®", said Jonathan Ross ...

Paladin and Auxilium Sign Exclusive Distribution Agreement for ...  -  Dec 12, 2006
Genetic Engineering News (press release),...and knowledge of the testosterone replacement market and will further strengthen our growing urology franchise which includes Oxytrol(R) and Trelstar(R)", said ...

Watson Pharma 3Q Profit Falls on Costs  Nov 7, 2006
II, but branded sales fell 7 percent to $85.6 million due to a decline in sales of Ferrlecit within Watson's nephrology franchise and lower pricing on Trelstar ... -MSN Money Paladin Reports Record Revenues for Third Quarter & Increases ...  Nov 2, 2006
Increased selling and marketing expenses in 2006 have resulted primarily from increased promotion activities behind the launch of Twinject(R), Trelstar(R) and ... -Genetic Engineering News (press release), Prostate Cancer Hormone Therapy May Have Unwelcome Side Effects  Oct 30, 2006
...agonists. Common drugs in this class include leuprolide (Lupron, Viadur, Eligard), goserelin (Zoladex), and triptorelin (Trelstar). ... -ACS News Center, Debiopharm honors cancer research in Lausanne  Oct 11, 2006
...is known in particular for having several products such as Eloxatin®, treatment of choice for colorectal cancer, and Decapeptyl® and Trelstar® for prostate ... -innovations report, Paladin and Auxilium Sign Exclusive Distribution Agreement for ...  -  12 Dec 2006
CCNMatthews (press release),...strengthen our growing urology franchise which includes Oxytrol ® and Trelstar ® ", said Jonathan Ross Goodman, President and CEO of Paladin Labs

Paladin and Auxilium Sign Exclusive Distribution Agreement for ...  -  12 Dec 2006
Genetic Engineering News (press release),...strengthen our growing urology franchise which includes Oxytrol(R) and Trelstar(R)", said Jonathan Ross Goodman, President and CEO of Paladin Labs

Paladin Reports Record Second Quarter Results and Provides Upward ...  Aug 3, 2006
In the third quarter, we will be launching Trelstar ® (LHRH) and Vantas ® (Histrelin Hydrogel Implant) for advanced prostate cancer. ... -CCNMatthews

GPC Biotech AG and Debiopharm SA Announce Partnering  Aug 7, 2006
...registered three products: Eloxatin®, one of Sanofi-Aventis’ leading marketed products, Decapeptyl®, the leading product of Ipsen, and Trelstar® (1-and 3 ... -Biotechnology Investment Today

Trelstar® Depot and Trelstar® La Available Nationwide  Jun 30, 2006
Trelstar® Depot and Trelstar® La are now available nationwide for the palliative treatment of advanced prostate cancer. Watson Pharmaceuticals, Inc. ... -Cancer Consultants



Paladin Reports 2006 First Quarter Financial Results  May 11, 2006
..."We exceeded our sales goals for the quarter, and are preparing to launch Vantas ® , and Trelstar ® , two products for the treatment of prostate cancer that ... - CCNMatthews

Debiopharm presents Phase I monthly implant and Phase II daily or ...  Apr 25, 2006
...in excess of $2.2bn in 2005: Eloxatin®, one of sanofi-aventis' leading marketed products; Decapeptyl®, the leading product of Ipsen; and Trelstar® (1-and 3 ... - PharmaLive.com





Debiopharm SA Invests in Nanocarrier Mezzanine Funding Round  Mar 30, 2006
...in excess of $2.2bn in 2005: Eloxatin®, one of sanofi-aventis' leading marketed products; Decapeptyl®, the leading product of Ipsen; and Trelstar® (1-and 3 ... - Yahoo! News

Debiopharm SA Invests in Nanocarrier Mezzanine Funding Round  Mar 30, 2006
...in excess of $2.2bn in 2005: Eloxatin(R), one of sanofi-aventis' leading marketed products; Decapeptyl(R), the leading product of Ipsen; and Trelstar(R) (1-and ... - PharmaLive.com



Debiopharm SA Presented Results of a Double-Blind Placebo ...  Feb 9, 2006
...in excess of $2.2bn in 2005: Eloxatin(R), one of sanofi-aventis' leading marketed products; Decapeptyl(R), the leading product of Ipsen; and Trelstar(R) (1-and ... - Canada NewsWire,

Debiopharm SA Presented Results of a Double-Blind Placebo ...  09 Feb 2006
...in excess of $2.2bn in 2005: Eloxatin®, one of sanofi-aventis' leading marketed products; Decapeptyl®, the leading product of Ipsen; and Trelstar® (1-and 3 ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional